Cargando…

Possible Modulatory Role of ARC Gene Variants in Mood Disorders

OBJECTIVE: The genetic background of mood disorders is gradually emerging through the use of large multicenter samples but a detailed phenotyping is complementary in elucidating the role of modulating variants. METHODS: In the present paper we focused on the possible modulatory effects of ARC gene v...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crisafulli, Concetta, Calabrò, Marco, Mandelli, Laura, Wang, Sheng-Min, Lee, Soo-Jung, Han, Changsu, Patkar, Ashwin, Masand, Prakash, Pae, Chi-Un, Souery, Daniel, Mendlewicz, Julien, Serretti, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean College of Neuropsychopharmacology 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851469/ https://www.ncbi.nlm.nih.gov/pubmed/33508787 http://dx.doi.org/10.9758/cpn.2021.19.1.46

Ejemplares similares

ZNF804A Gene Variants Have a Cross-diagnostic Influence on Psychosis and Treatment Improvement in Mood Disorders
por: Calabrò, Marco, et al.
Publicado: (2020)

Genes Involved in Neurodevelopment, Neuroplasticity and Major Depression: No Association for CACNA1C, CHRNA7 and MAPK1
por: Calabrò, Marco, et al.
Publicado: (2019)

Neuroplasticity, Neurotransmission and Brain-Related Genes in Major Depression and Bipolar Disorder: Focus on Treatment Outcomes in an Asiatic Sample
por: Calabrò, Marco, et al.
Publicado: (2018)

A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial
por: Han, Changsu, et al.
Publicado: (2018)

Corrigendum: A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial
por: Han, Changsu, et al.
Publicado: (2020)

Genome-wide association study of antidepressant response: involvement of the inorganic cation transmembrane transporter activity pathway
por: Cocchi, Enrico, et al.
Publicado: (2016)

Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection
por: Wang, Sheng-Min, et al.
Publicado: (2014)

Vilazodone for the Treatment of Major Depressive Disorder: Focusing on Its Clinical Studies and Mechanism of Action
por: Wang, Sheng-Min, et al.
Publicado: (2015)

Vilazodone for the Treatment of Depression: An Update
por: Wang, Sheng-Min, et al.
Publicado: (2016)

Effectiveness and Tolerability of Switching to Aripiprazole Once Monthly from Antipsychotic Polypharmacy and/or Other Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study
por: Pae, Chi-Un, et al.
Publicado: (2020)

Clinical Benefit and Utility of Switching to Aripiprazole Once Monthly in Patients with Antipsychotic Polypharmacy or Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study
por: Pae, Chi-Un, et al.
Publicado: (2021)

Consideration of Long-Acting Injectable Antipsychotics for Polypharmacy Regimen in the Treatment of Schizophrenia: Put It on the Table or Not?
por: Pae, Chi-Un, et al.
Publicado: (2021)

The Influence of AHI1 Variants on the Diagnosis and Treatment Outcome in Schizophrenia
por: Porcelli, Stefano, et al.
Publicado: (2015)

Abelson Helper Integration Site-1 Gene Variants on Major Depressive Disorder and Bipolar Disorder
por: Porcelli, Stefano, et al.
Publicado: (2014)

Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update
por: Wang, Sheng-Min, et al.
Publicado: (2016)

Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review
por: Wang, Sheng-Min, et al.
Publicado: (2018)

Erratum: Correction of Acknowledgements Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update
por: Wang, Sheng-Min, et al.
Publicado: (2019)

The Potential Utility of Aripiprazole Augmentation for Major Depressive Disorder with Mixed Features Specifier: A Retrospective Study
por: Han, Changsu, et al.
Publicado: (2019)

Exploring Hidden Issues in the Use of Antipsychotic Polypharmacy in the Treatment of Schizophrenia
por: Kim, Jung-Jin, et al.
Publicado: (2021)

Epistatic Interactions between CREB and CREM Variants in Affective Disorder
por: Chiesa, Alberto, et al.
Publicado: (2014)

Does Pregabalin Have Neuropsychotropic Effects?: A Short Perspective
por: Marks, David M., et al.
Publicado: (2009)

Acute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study
por: Lee, Seung-Hoon, et al.
Publicado: (2022)

Acute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study
por: Lee, Seung-Hoon, et al.
Publicado: (2022)

Additional Clinical Benefit of Agomelatine Treatment for Major Depressive Disorder in Naturalistic Treatment Setting
por: Lee, Kyung Ho, et al.
Publicado: (2023)

PM449. Hot genes in schizophrenia: case-control, pharmacogenetics and exploratory analyses in two independent samples
por: Porcelli, Stefano, et al.
Publicado: (2016)

Investigating the effectiveness of a smart mental health intervention (inMind) for stress reduction during pharmacological treatment for mild to moderate major depressive disorders: Study protocol for a randomized control trial
por: Kim, Junhyung, et al.
Publicado: (2023)

Efficacy and Safety of Escitalopram, Desvenlafaxine, and Vortioxetine in the Acute Treatment of Anxious Depression: A Randomized Rater-blinded 6-week Clinical Trial
por: Shin, Cheolmin, et al.
Publicado: (2023)

Serotonin-Norepinephrine Reuptake Inhibitors for Pain Control: Premise and Promise
por: Marks, David M, et al.
Publicado: (2009)

Effect of the Dysbindin Gene on Antimanic Agents in Patients with Bipolar I Disorder
por: Yun, Dong-Hwan, et al.
Publicado: (2008)

Triple Reuptake Inhibitors: The Next Generation of Antidepressants
por: Marks, David M, et al.
Publicado: (2008)

Triple Reuptake Inhibitors: A Premise and Promise
por: Marks, David M., et al.
Publicado: (2008)

The Genetics of Treatment-Resistant Depression: A Critical Review and Future Perspectives
por: Fabbri, Chiara, et al.
Publicado: (2018)

Clinical correlates of augmentation/combination treatment strategies in major depressive disorder
por: Dold, M., et al.
Publicado: (2018)

Pain and Depression: A Neurobiological Perspective of Their Relationship
por: Han, Changsu, et al.
Publicado: (2015)

Polygenic risk scores for neuropsychiatric, inflammatory, and cardio‐metabolic traits highlight possible genetic overlap with suicide attempt and treatment‐emergent suicidal ideation
por: Fanelli, Giuseppe, et al.
Publicado: (2022)

PS75. Psychopharmacoepidemiology of Major Depressive Disorder in European Tertiary Psychiatric Treatment Centers
por: Bartova, Lucie, et al.
Publicado: (2016)

Additional Reduction of Residual Symptoms with Aripiprazole Augmentation in the Patients with Partially Remitted Major Depressive Disorder
por: Shin, Cheolmin, et al.
Publicado: (2021)

Dimensions of Delusions in Major Depression: Socio-demographic and Clinical Correlates in an Unipolar-Bipolar Sample
por: Zaninotto, Leonardo, et al.
Publicado: (2015)

Omega-3 Polyunsaturated Fatty Acids in Prevention of Mood and Anxiety Disorders
por: Su, Kuan-Pin, et al.
Publicado: (2015)

The Impact of BDNF Polymorphisms on Suicidality in Treatment-Resistant Major Depressive Disorder: A European Multicenter Study
por: Schosser, Alexandra, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_icn8b8u9h0snrtr10r9f1bq7cf